Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database

Overview

Journal Gut Liver

Specialty Gastroenterology

Date 2018 Jun 26

PMID 29938462

Citations 36

Authors

Byung-Woo Kim

Chang-Mo Oh

Hwa Young Choi

Joong-Won Park

Hyunsoon Cho

Moran Ki

Affiliations

Soon will be listed here.

Abstract

Background/aims: There have been no nationwide studies to investigate the trends in incidence and 5-year survival rates of intra- and extrahepatic bile duct cancers and gallbladder cancer. Therefore, our study aimed to describe the incidence and 5-year survival rates of biliary tract cancers by subsites in South Korea.

Methods: A total of 86,134 patients with biliary tract cancers were selected from the National Health Information Database. Age-standardized incidence rates and annual percentage changes were calculated. Lifetable methods and log-rank tests were used to determine the differences in survival rates. Cox-proportional hazard models were used to estimate the hazard ratio of the patients with biliary tract cancers.

Results: The incidence rate of intrahepatic bile duct cancer decreased by 1.3% annually from 8.8 per 100,000 in 2006 to 7.8 per 100,000 in 2015. Extrahepatic bile duct cancer also showed a decreasing trend by 2.2% per year from 8.7 per 100,000 in 2006 to 6.7 per 100,000 in 2015. Gallbladder cancer showed the greatest decline, with an annual percentage change of 2.8% from 6.3 per 100,000 to 5.2 per 100,000 during the same period. The 5-year survival rates were 30.0% in gallbladder cancer, 27.8% in extrahepatic bile duct cancer, and 15.9% in intrahepatic bile duct cancer.

Conclusions: The overall incidence rates of intrahepatic and extrahepatic bile duct cancer and gallbladder cancer decreased from 2006 to 2015. Among biliary tract cancers, intrahepatic bile duct cancers exhibited the highest incidence rate and the worst survival rate.

Citing Articles

Choledocholithiasis as a risk factor for cholangiocarcinoma: a nationwide retrospective cohort study.

Kim J, Lee Y, Lee J, Hwang J BMC Gastroenterol. 2025; 25(1):138.

PMID: 40045214 PMC: 11883955. DOI: 10.1186/s12876-025-03746-w.

Long-term tumor suppression in cholangiocarcinoma using cytokine-induced killer cell therapy and high-dose vitamin C: a case report.

Kim K, Wang H, Lee J, Yeom C Korean J Clin Oncol. 2025; 20(2):84-87.

PMID: 39778511 PMC: 11717578. DOI: 10.14216/kjco.24012.

The Catheter Flushing Method Shows a Similar Diagnostic Yield to the Conventional Method in Brushing Cytology for Biliary Strictures.

Jang S, Nahm J, Lee S, Jeong S, Lee T, Kim D J Clin Med. 2024; 13(22).

PMID: 39597885 PMC: 11594799. DOI: 10.3390/jcm13226741.

Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial.

Xu L, Yuan J, Xue R, Zhou J World J Gastroenterol. 2024; 30(30):3564-3573.

PMID: 39193574 PMC: 11346148. DOI: 10.3748/wjg.v30.i30.3564.

Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies.

Lou Y, Chen Y, Guo K, Li B, Zheng S Biomark Med. 2024; 18(15-16):703-715.

PMID: 39143949 PMC: 11441040. DOI: 10.1080/17520363.2024.2385297.

References

Datta R, LaQuaglia M, Paty P . Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med. 2000; 342(2):137-8. DOI: 10.1056/NEJM200001133420216. View

Khan S, Taylor-Robinson S, Toledano M, Beck A, Elliott P, Thomas H . Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; 37(6):806-13. DOI: 10.1016/s0168-8278(02)00297-0. View

Shaib Y, Davila J, McGlynn K, El-Serag H . Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol. 2004; 40(3):472-7. DOI: 10.1016/j.jhep.2003.11.030. View

West J, Wood H, Logan R, Quinn M, Aithal G . Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006; 94(11):1751-8. PMC: 2361300. DOI: 10.1038/sj.bjc.6603127. View

Jepsen P, Vilstrup H, Tarone R, Friis S, Sorensen H . Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst. 2007; 99(11):895-7. DOI: 10.1093/jnci/djk201. View

Randi G, Malvezzi M, Levi F, Ferlay J, Negri E, Franceschi S . Epidemiology of biliary tract cancers: an update. Ann Oncol. 2008; 20(1):146-59. DOI: 10.1093/annonc/mdn533. View

Shin H, Oh J, Lim M, Shin A, Kong H, Jung K . Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010; 25(7):1011-6. PMC: 2890876. DOI: 10.3346/jkms.2010.25.7.1011. View

Lepage C, Cottet V, Chauvenet M, Phelip J, Bedenne L, Faivre J . Trends in the incidence and management of biliary tract cancer: a French population-based study. J Hepatol. 2010; 54(2):306-10. DOI: 10.1016/j.jhep.2010.06.039. View

Rustagi T, Dasanu C . Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates. J Gastrointest Cancer. 2011; 43(2):137-47. DOI: 10.1007/s12029-011-9284-y. View

10.

Lee B, Cho Y, Jeong S, Lee J, Lee D, Park N . Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs. J Med Virol. 2013; 85(8):1327-33. DOI: 10.1002/jmv.23594. View

11.

Kim H, Shin A, Chung H, Kim M, Lee J, Shim J . Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med. 2013; 28(4):413-9. PMC: 3712149. DOI: 10.3904/kjim.2013.28.4.413. View

12.

Pinter M, Hucke F, Zielonke N, Waldhor T, Trauner M, Peck-Radosavljevic M . Incidence and mortality trends for biliary tract cancers in Austria. Liver Int. 2013; 34(7):1102-8. DOI: 10.1111/liv.12325. View

13.

Utada M, Ohno Y, Tamaki T, Sobue T, Endo G . Long-term trends in incidence and mortality of intrahepatic and extrahepatic bile duct cancer in Japan. J Epidemiol. 2014; 24(3):193-9. PMC: 4000766. DOI: 10.2188/jea.je20130122. View

14.

Hundal R, Shaffer E . Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014; 6:99-109. PMC: 3952897. DOI: 10.2147/CLEP.S37357. View

15.

Kwon G, Lee H, Gwack J, Lee S, Ki M, Youn S . Regional distribution of hepatitis C virus infection in the Republic of Korea, 2007-2011. Gut Liver. 2014; 8(4):428-32. PMC: 4113042. DOI: 10.5009/gnl.2014.8.4.428. View

16.

Chan E, Berlin J . Biliary tract cancers: understudied and poorly understood. J Clin Oncol. 2015; 33(16):1845-8. DOI: 10.1200/JCO.2014.59.7591. View

17.

Oh C, Won Y, Cho H, Lee J, Park B, Jun J . Alanine aminotransferase and gamma-glutamyl transferase have different dose-response relationships with risk of mortality by age. Liver Int. 2015; 36(1):126-35. DOI: 10.1111/liv.12879. View

18.

Potkonjak M, Miura J, Turaga K, Johnston F, Tsai S, Christians K . Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. HPB (Oxford). 2015; 17(12):1119-23. PMC: 4644364. DOI: 10.1111/hpb.12504. View

19.

Mosadeghi S, Liu B, Bhuket T, Wong R . Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000-2011 Surveillance, Epidemiology and End Results registry. Hepatol Res. 2015; 46(7):669-77. DOI: 10.1111/hepr.12605. View

20.

Shon H, Choi H, Kim J, Ryu S, Lee Y, Lee M . Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005-2012. Clin Mol Hepatol. 2015; 21(3):249-56. PMC: 4612286. DOI: 10.3350/cmh.2015.21.3.249. View